Predictors of uptake of 4 weeks or more of antenatal combination antiretroviral therapy, 2011–2016
| Variable | OR (95% CI) | |
|---|---|---|
| Univariate | Multivariate | |
| Maternal risk category | ||
| Heterosexual v. injection drug use | 2.09 (1.28–3.42) | 1.55 (0.77–3.11) |
| Perinatal v. injection drug use | 1.10 (0.31–3.86) | 0.77 (0.21–2.82) |
| Other* v. injection drug use | 4.21 (0.56–31.93) | 1.61 (0.28–9.17) |
| Maternal race/ethnicity | ||
| Black v. Indigenous | 2.16 (1.30–3.59) | 2.99 (1.23–7.26) |
| White v. Indigenous | 1.19 (0.66–2.13) | 1.60 (0.69–3.70) |
| Other v. Indigenous | 2.46 (0.85–7.18) | 2.12 (0.65–6.87) |
| Black v. white | 1.82 (1.04–3.19) | 1.87 (0.99–1.27) |
| Province/territory† | ||
| British Columbia/Yukon Territory v. Alberta | 2.45 (0.89–6.74) | 3.31 (1.06–10.32) |
| British Columbia/Yukon Territory v. Saskatchewan | 2.32 (0.81–6.68) | 1.33 (0.42–4.24) |
| British Columbia/Yukon Territory v. Manitoba | 1.99 (0.61–6.44) | 2.14 (0.63–7.29) |
| British Columbia/Yukon Territory v. Ontario | 1.98 (0.76–5.16) | 3.16 (1.08–9.26) |
| British Columbia/Yukon Territory v. Quebec | 1.88 (0.67–5.30) | 3.44 (1.09–10.84) |
| British Columbia/Yukon Territory v. Atlantic provinces | 5.68 (0.56–58.08) | 5.48 (0.10–314.49) |
| Infant birth year | 1.05‡ (0.93–1.19) | 1.10‡ (0.96–1.27) |
| Gestational age at birth | 1.07 (0.99–1.15) | 1.04 (0.95–1.14) |